Healthcare
Live Price
Offline$74.96
+3.19% today
1Y Change
+43.57%
Window
Jun 27, 2025 → Jun 26, 2026
Coverage: 250 bars · Jun 27, 2025 → Jun 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Halozyme Therapeutics, Inc. (HALO) is a Healthcare stock with a market cap of $7.54B and listed on NASDAQ. The stock last traded around $74.96 and up 43.6% across the available one-year price window (Jun 27, 2025 → Jun 26, 2026). Baseline metrics include revenue growth of +37.6%, EPS growth of -24.6%, a dividend yield of 0.0%. What stands out right now is revenue +37.6%, EPS -24.6%, free cash flow +37.6% with operating margin 58.4% and ROIC 23.6%. Valuation sits in the middle of the pack at P/E 23.6 and price/sales 5.4. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines HALO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HALO
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HALO Max Drawdown
-24.13%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for HALO and SPY.
Unable to load analyst forecasts.
Timed out loading forecasts for HALO
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.